Literature DB >> 7583521

Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and Cox 2 inhibitors.

C J Grossman1, J Wiseman, F S Lucas, M A Trevethick, P J Birch.   

Abstract

A range of NSAIDs and reported Cox 2 selective compounds were tested in human freshly isolated platelets and LPS-stimulated mononuclear cells to determine their potency and selectivity as inhibitors of constitutive (presumably Cox 1) and inducible (presumably Cox 2) cyclooxygenase respectively. All compounds tested were either equipotent at inhibiting constitutive and inducible cyclooxygenase or were selective for the inducible form. The most selective compound was Dup697 and the least selective, ketoprofen. Several compounds only produced a partial inhibition of constitutive cyclooxygenase as the maximum inhibitor concentration achievable in the assay was limited to 1 mM. With the exception of paracetamol, all compounds were able to produce full inhibition curves against the inducible form. Potency estimates against constitutive Cox compare closely with published data but most compounds were consistently more potent against the inducible isoform than in published data for human cloned, microsomal Cox 2. These data suggest that human mononuclear cells are either exquisitely sensitive to some NSAIDs or they may contain another Cox isoform as yet indistinguishable from Cox 2.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7583521     DOI: 10.1007/BF01782978

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  19 in total

1.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

2.  Nabumetone (BRL 14777, 4-[6-methoxy-2-naphthyl]-butan-2-one): a new anti-inflammatory agent.

Authors:  E A Boyle; P C Freeman; F R Mangan; M J Thomson
Journal:  J Pharm Pharmacol       Date:  1982-09       Impact factor: 3.765

3.  NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions.

Authors:  N Futaki; K Yoshikawa; Y Hamasaka; I Arai; S Higuchi; H Iizuka; S Otomo
Journal:  Gen Pharmacol       Date:  1993-01

4.  Lipopolysaccharide induces prostaglandin H synthase-2 in alveolar macrophages.

Authors:  M G O'Sullivan; E M Huggins; E A Meade; D L DeWitt; C E McCall
Journal:  Biochem Biophys Res Commun       Date:  1992-09-16       Impact factor: 3.575

5.  Differentiation-associated expression of prostaglandin G/H synthase in monocytic cells.

Authors:  T Hoff; D DeWitt; V Kaever; K Resch; M Goppelt-Struebe
Journal:  FEBS Lett       Date:  1993-03-29       Impact factor: 4.124

6.  Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system.

Authors:  J Barnett; J Chow; D Ives; M Chiou; R Mackenzie; E Osen; B Nguyen; S Tsing; C Bach; J Freire
Journal:  Biochim Biophys Acta       Date:  1994-11-16

7.  NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro.

Authors:  N Futaki; S Takahashi; M Yokoyama; I Arai; S Higuchi; S Otomo
Journal:  Prostaglandins       Date:  1994-01

8.  Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor.

Authors:  K R Gans; W Galbraith; R J Roman; S B Haber; J S Kerr; W K Schmidt; C Smith; W E Hewes; N R Ackerman
Journal:  J Pharmacol Exp Ther       Date:  1990-07       Impact factor: 4.030

9.  Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs.

Authors:  M C Allison; A G Howatson; C J Torrance; F D Lee; R I Russell
Journal:  N Engl J Med       Date:  1992-09-10       Impact factor: 91.245

10.  Studies on antiinflammatory agents. I. Synthesis and pharmacological properties of 2'-phenoxymethanesulfonanilide derivatives.

Authors:  K Tsuji; K Nakamura; N Konishi; H Okumura; M Matsuo
Journal:  Chem Pharm Bull (Tokyo)       Date:  1992-09       Impact factor: 1.645

View more
  13 in total

1.  Interaction of cyclooxygenases with an apoptosis- and autoimmunity-associated protein.

Authors:  B A Ballif; N V Mincek; J T Barratt; M L Wilson; D L Simmons
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

2.  Anti-inflammatory activity of topical nimesulide gel in various experimental models.

Authors:  S K Gupta; J Prakash; L Awor; S Joshi; T Velpandian; S Sengupta
Journal:  Inflamm Res       Date:  1996-12       Impact factor: 4.575

Review 3.  Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs.

Authors:  J Y Jouzeau; B Terlain; A Abid; E Nédélec; P Netter
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

4.  Modulation of acute and chronic inflammatory processes by cacospongionolide B, a novel inhibitor of human synovial phospholipase A2.

Authors:  P García Pastor; S De Rosa; A De Giulio; M Payá; M J Alcaraz
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

5.  The effects of cyclooxygenase 2 inhibitors on cartilage erosion and bone loss in a model of Mycobacterium tuberculosis-induced monoarticular arthritis in the rat.

Authors:  D W Gilroy; A Tomlinson; K Greenslade; M P Seed; D A Willoughby
Journal:  Inflammation       Date:  1998-10       Impact factor: 4.092

Review 6.  The role of COX-2 inhibitors in pain modulation.

Authors:  Frederic Camu; Lin Shi; Caroline Vanlersberghe
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Ex vivo effects of lysine clonixinate on cyclooxygenases in rat lung and stomach preparations.

Authors:  A M Franchi; G Di Girolamo; A R De los Santos; M L Marti; M A Gimeno
Journal:  Inflammopharmacology       Date:  1999       Impact factor: 4.473

8.  Selective prostaglandin G/H synthase (PGHS)-2 inhibitors show greater inhibitory activities on human PGHS-2 than on murine PGHS-2 in intact cells.

Authors:  J Berg; H Fellier; A Bodenteich; T Christoph; R Towart
Journal:  Inflammopharmacology       Date:  1997       Impact factor: 4.473

Review 9.  Clinical pharmacokinetics of nimesulide.

Authors:  A Bernareggi
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

10.  Mechanism of enhancement of intestinal ulcerogenicity of S-aryl propionic acids by their R-enantiomers in the rat.

Authors:  W J Wechter; J D McCracken; D Kantoci; E D Murray; D Quiggle; D Leipold; K Gibson; Y Mineyama; Y Liu
Journal:  Dig Dis Sci       Date:  1998-06       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.